Complement activity and pharmacological inhibition in cardiovascular disease.
While complement is the most important component of humoral autoimmunity, and inflammation plays a key role in atherosclerosis, relatively few studies have looked at complement implications in atherosclerosis and its complications. C-reactive protein is a marker of inflammation and is also involved in atherosclerosis; it activates complement and colocalizes with activated complement proteins within the infarcting myocardium and the active atherosclerotic plaques. As new agents capable of modulating complement activity are being developed, new targets for the management of atherosclerosis are emerging that are related to autoimmunity and inflammation. The present paper reviews the putative roles of the various complement activation pathways in the development of atherosclerosis, in ST segment elevation and non-ST segment elevation acute coronary syndromes, and in coronary artery bypass graft surgery. It also provides a perspective on new therapeutic interventions being developed to modulate complement activity. These interventions include the C1 esterase inhibitor, which may be consumed in some inflammatory states resulting in the loss of one of the mechanisms inhibiting activation of the classical and lectin pathways; TP10, a recombinant protein of the soluble complement receptor type 1 (sCR1) which inhibits the C3 and C5 convertases of the common pathway by binding C3b and C4b; a truncated version of the soluble complement receptor type 1 CRI lacking the C4b binding site which selectively inhibits the alternative pathway; and pexelizumab, a monoclonal antibody selectively blocking C5 to prevent the activation of the terminal pathway that is involved in excessive inflammation and autoimmune responses.
University of Montreal, Montreal, Quebec. pierre.theroux@icm-mhi.org
Pierre
P
Théroux
Catherine
C
Martel
D000789:Angina, Unstable / Q000276:immunology; D000818:Animals; D050197:Atherosclerosis / Q000276:immunology*; D015551:Autoimmunity / Q000276:immunology; D002318:Cardiovascular Diseases / Q000276:immunology*; D003167:Complement Activation; D051056:Complement Inactivating Agents / Q000494:pharmacology / Q000627:therapeutic use; D003171:Complement Pathway, Classical; D003165:Complement System Proteins / Q000276:immunology; D001026:Coronary Artery Bypass; D006801:Humans; D007249:Inflammation; D009203:Myocardial Infarction / Q000276:immunology
D051056:Complement Inactivating Agents; D003165:Complement System Proteins